The 53 references in paper S. Avdeev N., С. Авдеев Н. (2014) “Современные подходы к антибактериальной терапии обострений хронической обструктивной болезни легких // Current approach to antibacterial therapy of acute exacerbation of chronic obstructive pulmonary disease” / spz:neicon:pulmonology:y:2012:i:3:p:109-114

1
Murray C.J.L., Lopez A.D.Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997; 349: 1269–1276.
(check this in PDF content)
2
Mannino D.M., Homa D.M., Akinbami L.J. et al.Chronic obstructive pulmonary disease surveillance – United States, 1971–2000. MMWR Surveill. Summ. 2002; 51: 1–16.
(check this in PDF content)
3
Lopez A.D., Shibuya K., Rao C. et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur. Respir. J. 2006; 27: 397–412.
(check this in PDF content)
4
Zielinski J., MacNee W., Wedzicha J., et al.Causes of death in patients with COPD and chronic respiratory failure. Monaldi Arch. Chest Dis. 1997; 52: 43–47.
(check this in PDF content)
5
Groenewegen K.H., Schols A.M., Wouters E.F. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 2003; 124: 459–467.
(check this in PDF content)
6
Hurst J.R., Vestbo J., Anzueto A. et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 2010; 363: 1128–1138.
(check this in PDF content)
7
Global initiative for chronic obstructive lung disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI / WHO workshop report. Last updated 2011. www.goldcopd.org
(check this in PDF content)
8
Donaldson G.C., Wedzicha J.A.COPD exacerbations: epidemiology. Thorax 2006; 61: 164–168.
(check this in PDF content)
9
Celli B.R., Barnes P.J.Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Eur. Respir. J. 2007; 29: 1224–1238.
(check this in PDF content)
10
Smeeth L., Thomas S.L., Hall A.J. et al. Risk of myocardial infarction and stroke after acute infection or vaccination. N. Engl. J. Med. 2004; 351: 2611–2618.
(check this in PDF content)
11
Papi A., Bellettato C.M., Braccioni F. et al.Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am. J. Respir. Crit. Care Med. 2006; 173: 1114–1121.
(check this in PDF content)
12
Veeramachaneni S.B., Sethi S. Pathogenesis of bacterial exacerbations of COPD. COPD 2006; 3: 109–115.
(check this in PDF content)
13
Eller J., Ede A., Schaberg T. et al.Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest 1998; 113: 1542–1548.
(check this in PDF content)
14
Hirschmann J.V. Do bacteria cause exacerbations of COPD? Chest 2000; 118; 193–203.
(check this in PDF content)
15
Puhan M.A., Vollenweider D., Latshang T. et al.Exacerbations of chronic obstructive pulmonary disease: when are antibiotics indicated? A systematic review. Respir. Res. 2007; 8: 30.
(check this in PDF content)
16
Woodhead M., Blasi F., Ewig S. et al.; European Respiratory Society; European Society of Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections. Eur. Respir. J. 2005; 26: 1138–1180.
(check this in PDF content)
17
O'Donnell D.E., Hernandez P., Kaplan A. et al.Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2008 update – highlights for primary care. Can. Respir. J. 2008; 15 (Suppl. A): 1A–8A.
(check this in PDF content)
18
Anthonisen N.R., Manfreda J., Warren C.P. et al.Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 1987; 106: 196–204.
(check this in PDF content)
19
Celli B.R., MacNee W.; ATS / ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS / ERS position paper. Eur. Respir. J. 2004; 23: 932–946. Рис. 4. Время до клинической неудачи после терапии обострений ХОБЛ моксифлоксацином и амоксициллином / клавуланатом [50]
(check this in PDF content)
20
Bafadhel M., McKenna S., Terry S. et al.Acute exacerbations of chronic obstructive pulmonary disease. Identification of biologic clusters and their biomarkers. Am. J. Respir. Crit. Care Med. 2011; 184: 662–671.
(check this in PDF content)
21
Weis N., Almdal T.C-reactive protein – can it be used as a marker of infection in patients with exacerbation of chronic obstructive pulmonary disease. Eur. J. Intern. Med. 2006; 17: 88–91.
(check this in PDF content)
22
Dev D., Sankaran E.W.R., Cunnife J. et al.Value of C-reactive protein in exacerbation of chronic obstructive pulmonary disease. Respir. Med. 1998; 92: 664–667.
(check this in PDF content)
23
Авдеев С.Н., Баймаканова Г.Е., Зубаирова П.А.Возможности С-реактивного белка в диагностике бактериальной инфекции и пневмонии у больных с обострением хронической обструктивной болезни легких. Урал. мед. журн. 2008; 13: 19–24.
(check this in PDF content)
24
Wilson R., Jones P., Schaberg T. et al.Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis. Thorax 2006; 61: 337–342.
(check this in PDF content)
25
Martinez F., Han M., Flaherty K., Curtis J. Role of infection and antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease. Exp. Rev. Anti Infect. Ther. 2006; 4: 101–124.
(check this in PDF content)
26
Козлов Р.С., Сивая О.В., Кречикова О.И. и др.Динамика резистентности Streptococcus pneumoniae к антибиотикам в России за период 1999–2009 гг. (Результаты многоцентрового проспективного исследования ПеГАС). Клин микробиол. антимикроб. химиотер. 2010; 12 (4): 329–341.
(check this in PDF content)
27
Siempos I.I., Dimopoulos G., Korbila I.P. et al.Macrolides, quinolones and amoxicillin / clavulanate for chronic bronchitis: a meta-analysis. Eur. Respir. J. 2007; 29: 1127–1137.
(check this in PDF content)
28
Anzueto A., Fisher C.L. Jr., Busman T., Olson C.A. Comparison of the efficacy of extended-release clarithromycin tablets and amoxicillin / clavulanate tablets in the treatment of acute exacerbation of chronic bronchitis. Clin. Ther. 2001; 23: 72–86.
(check this in PDF content)
29
Amsden G.W., Baird I.M., Simon S., Treadway G. Efficacy and safety of azithromycin versus levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis. Chest 2003; 123: 772–777.
(check this in PDF content)
30
Andre'Alves M.R., Jardim J.R., Silva R.F. et al. Comparison between azithromycin and amoxicillin in the treatment of infectious exacerbation of chronic obstructive pulmonary disease. J. Bras. Pneumol. 2007; 33: 43–50.
(check this in PDF content)
31
Rubin B.K.Immunomodulatory properties of macrolides: overview and historical perspective. Amer. J. Med. 2004; 117.(9A): 2S–4S.
(check this in PDF content)
32
EUCAST Expert rules in antimicrobial susceptibility testing, version 1, April 2008. http:// www.EUCAST.org
(check this in PDF content)
33
O'Donnell J.A., Gelone S.P.The newer fluoroquinolones. Infect. Dis. Clin. N. Am. 2004; 18: 691–716.
(check this in PDF content)
34
Blasi F., Tarsia P., Aliberti S. et al.Highlights on the appropriate use of fluoroquinolones in respiratory tract infections. Pulm. Pharmacol. Therap. 2006; 19: 11–19.
(check this in PDF content)
35
Bonfiglio G. Is levofloxacin as active as ciprofloxacin against Pseudomonas aeruginosa? Chemotherapy 2001; 47: 239–242.
(check this in PDF content)
36
Greenberg R.N. Overview of patient compliance with medication dosing: a literature review. Clin. Ther. 1994; 6: 592–599.
(check this in PDF content)
37
Sethi S., Fogarty C., Fulambarker A.A randomized, doubleblind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis. Respir. Med. 2004; 98: 697–707.
(check this in PDF content)
38
Lode H., Eller J., Linnhoff A., Ioanas M. The Evaluation of Therapy-Free Interval in COPD Patients Study Group. Levofloxacin versus clarithromycin in COPD exacerbation: focus on exacerbation-free interval. Eur. Respir. J. 2004; 24: 947–953.
(check this in PDF content)
39
Wilson R., Allerga L., Huchon G. et al. Short-term and longterm outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 2004; 125 (3): 953–964.
(check this in PDF content)
40
Geddes A.M., Klugman K.P., Rolinson G.N.Introduction: historical perspective and development of amoxicillin / clavulanate. Int. J. Antimicrob. Agents 2007; Suppl. 2: S109–S112.
(check this in PDF content)
41
McIvor R.A.Antibiotics in acute exacerbations of chronic obstructive pulmonary disease. Can. Fam. Physician. 2009; 55: 15–16, 19–21.
(check this in PDF content)
42
Сидоренко С.В., Козлов С.Н.Группа пенициллинов. В кн.: Страчунский Л.С., Белоусов Ю.Б., Козлов С.Н. (ред.). Практическое руководство по антиинфекционной химиотерапии. М.: Боргес; 2002. 47–55.
(check this in PDF content)
43
Beghi G., Berni F., Carratu L. et al.Efficacy and tolerability of azithromycin versus amoxicillin clavulanic acid in acute purulent exacerbation of chronic bronchitis. J. Chemother 1995; 7: 146–152.
(check this in PDF content)
44
Canut A., Martιn'Herrero J.E., Labora A., Maortua H.What are the most appropriate antibiotics for the treatment of acute exacerbation of chronic obstructive pulmonary disease? A therapeutic outcomes model. J. Antimicrob. Chemother. 2007; 60: 605–612.
(check this in PDF content)
45
Llor C., Naberan K., Cots J.M. et al.Risk factors for increased cost of exacerbations of chronic bronchitis and chronic obstructive pulmonary disease. Arch. Bronconeumol. 2006; 42: 175–182.
(check this in PDF content)
46
Sourgens H., Steinbrede H., Verschoor J.S. et al. Bioequivalence study of a novel Solutab tablet formulation of amoxicillin / clavulanic acid versus the originator film-coated tablet. Int. J. Clin. Pharmacol. Ther. 2001; 39: 75–82.
(check this in PDF content)
47
Карпов О.И. Флемоклав Солютаб – новая лекарственная форма амоксициллина / клавуланата в лечении синусита. Клиническая фармакология и терапия 2006; 15 (4): 1–4.
(check this in PDF content)
48
Cortvriendt W.R., Verschoor J.S., Hespe W. Bioavailability study of a new amoxicillin tablet designed for several modes of oral administration. Arzneimittelforschung 1987; 37: 977–979.
(check this in PDF content)
49
Гучев И.А., Козлов Р.С. Безопасность и эффективность различных лекарственных форм амоксициллина / клавулановой кислоты при инфекциях нижних дыхательных путей у взрослых: Открытое проспективное рандомизированное исследование. Пульмонология 2008; 2: 73–80.
(check this in PDF content)
50
Wilson R., Anzueto A., Miravitlles M. et al.A novel study design for antibiotic trials in acute exacerbations of COPD: MAESTRAL methodology. Int. J. COPD 2011; 6: 373–383.
(check this in PDF content)
51
Wilson R., Anzueto A., Miravitlles M. et al.Moxifloxacin vs amoxicillin / clavulanic acid in outpatient AECOPD: MAESTRAL results. Eur. Respir. J. erj00903-2011; published ahead of print December 1, 2011, doi:10.1183/09031936.00090311.
(check this in PDF content)
52
White A.J., Gompertz S., Bayley D.L. et al.Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax 2003; 58: 680–685.
(check this in PDF content)
53
Chodosh S.Clinical significance of the infection-free interval in the management of acute bacterial exacerbations of chronic bronchitis. Chest 2005; 127: 2231–2236. Сведения об авторе Авдеев Сергей Николаевич– д. м. н., проф., руководитель клиническо-
(check this in PDF content)